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Background: Psoriasis causes worldwide concern because of its high-prevalence, as well as its harmful, and
incurable characteristics. Topical therapy is a conventional treatment for psoriasis vulgaris. Chinese medicine (CM)
has been commonly used in an integrative way for psoriasis patients for many years. Some CM therapies have
shown therapeutic effects for psoriasis vulgaris (PV), including relieving symptoms and improving quality of life, and
may reduce the relapse rate. However, explicit evidence has not yet been obtained. The purpose of the present
trial is to examine the efficacy and safety of the YXBCM01 granule, a compound Chinese herbal medicine, with a
combination of topical therapy for PV patients.
Methods/Design: Using an add-on design, the trial is to evaluate whether the YXBCM01 granule combined topical
therapy is more effective than topical therapy alone for the treatment of PV. The study design is a double-blind,
parallel, randomized controlled trial comparing the YXBCM01 granule (5.5 g twice daily) to a placebo. The duration
of treatment is 12 weeks. A total of 600 participants will be randomly allocated into two groups, YXBCM01 granule
group and placebo group, from 11 general or dermatological hospitals in China. Topical use of calcipotriol
betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks will be the same standard
therapy for the two groups. Patients will be enrolled if they have a clinical diagnosis of PV, a psoriasis area severe
index (PASI) of more than 10 or body surface area (BSA) of more than 10%, but PASI of less than 30 and BSA of
less than 30%, are aged between 18 and 65-years-old, and provide signed informed consent. The primary outcome,
relapse rate, is based on PASI assessed blindly during the treatment. Secondary outcomes include: (i) relapse time
interval, (ii) time to onset, (iii) rebound rate, (iv) PASI score, (v) cumulative consumption of medicine, (vi) the
dermatology quality life index (DLQI), and (vii) the medical outcomes study (MOS) item short form health survey
(SF-36). Analysis will be on intention-to-treat and per-protocol subject analysis principles.
Discussion: To address the effectual remission of the YXBCM01 granule for PV, this trial may provide a novel
regimen for PV patients if the granule can decrease relapse rate without more adverse effects.
Trial registration: Chinese Clinical Trial Registry (www.chictr.org): ChiCTR-TRC-13003233, registered 26 May 2013.
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Psoriasis is an immune-abnormal, chronic, proliferative
skin disease determined by polygenic inheritance and
induced by a number of environmental factors. The
prevalence rates of psoriasis in Europe vary between
0.73% (in Scotland) and 2.9% (in Italy), and rates re-
ported in United States vary between 0.7% and 2.6%,
which shows a worldwide geographic variation [1]. In
China, the incidence of psoriasis has increased to 0.47%
[2], showing an upward trend of 0.12% compared to
1984 [3]. Psoriasis is characterized by scaly, erythema-
tous patches, papules, and plaques that are often se-
verely pruritic. Symptoms such as poor esteem, sexual
dysfunction, anxiety, depression, and suicidal ideation
due to the appearance of skin, can significantly reduce
the patients’ health-related quality of life. For instance,
in China, 59.8% of psoriatic people experience negative
influences on quality of life [2]. It has been a cause of in-
creasing concern worldwide due to its high-prevalence
and its harmful and incurable characteristics.
Topical therapies remain the primary method of man-
aging mild to moderate psoriasis, including topical cor-
ticosteroids, vitamin D analogues, sulfur ointment, laser
therapy, dithranol, tazarotene, and coal tar [4,5]. In par-
ticular situations, plaque psoriasis, erythrodermic psor-
iasis, generalized pustular psoriasis, and refractory cases
are treated with systematic therapy such as retinoic acid,
methotrexate, glucocorticoid, and biologicals. However,
most of the systematic therapies have serious side ef-
fects and are an expensive option, thus limiting their
long-term use [6].
Over the years, Chinese medicine (CM) for treatment
of psoriasis has accumulated a wealth of clinical experi-
ence. Some CM therapies have shown long lasting thera-
peutic effects on controlling psoriasis vulgaris (PV) with
minimal side effects. CM can also alleviate the symptoms
effectively, reduce the recurrence rate, and control the
condition with fewer side effects in psoriasis treatment
[7-9]. A systematic review of CM for psoriasis treatment,
including 32 randomized controlled trials worldwide,
reporting 5,179 patients with PV, suggested that some
certain CM interventions or combining CM with con-
ventional medicine had promising results for PV [10].
The topical herbal formula and herbal medicines adding
to conventional therapy for psoriasis appears to have
potential benefits for symptom reduction and is also
relatively safe [11,12]. However, there was previously no
evidence supporting CM as an effective and safe therapy
against PV relapse.
A Chinese herbal compound, YXBCM01 formula, is
theorized to have an effect on reducing PV’s relapse rate
based on Chinese medicine theory and clinical observa-
tions. This formula composed of Radix Paeoniae Rubra
(Chishao), Sarcandra Glabra (Jiujiecha), Rhizoma SmilacisGlabrae (Tufuling) and more, and was developed by Pro-
fessor Xuan Guowei, a well-known CM dermatologist in
China. YXBCM01 is the most commonly used formula to
treat PV in Guangdong Provincial Hospital of Chinese
Medicine (GPHCM) for over 20 years, and has been regis-
tered with the Guangdong Food and Drug Administration
(Hospital preparation approval number Z20080123). An
observational study showed two months treatment of
YXBCM01 for PV reduced Psoriasis Area Severe Index
(PASI) and Dermatology Life Quality Index (DLQI) scores,
moreover, no adverse reaction was reported during the
study period [13].
According to the German guidelines on treatment of PV,
topical therapy with a combination of calcipotriol beta-
methasone for the first 4 weeks and calcipotriol ointment
for the remaining 8 weeks is recommended, since it was
significantly superior from a pharmacoeconomic stand-
point when compared to the use of each therapy alone
[13]. Therefore, a randomized, double-blind, placebo-
controlled add-on study is designed to evaluate the effi-
cacy of YXBCM01 concurrent with topical therapy of
calcipotriol and betamethasone in reducing the relapse
rate of PV. Results of this study will provide evidence
regarding the value of YXBCM01 as an intervention for
PV patients.Method/Design
Design and setting
This is a multicenter, randomized controlled trial, which
will be conducted in 11 general or dermatological hospi-
tals in different provinces in China. The study aims to
enroll 600 patients with PV over a three-year period. Par-
ticipants are randomized using a ratio of 1:1 to receive ei-
ther an oral YXBCM01 granule (5.5 g twice daily) or a
placebo. After a 2 to 4 week run-in period for the screen-
ing of subjects and providing written informed consent,
patients will be randomly allocated into two groups to
undergo a treatment period of 12 weeks. A follow-up
period of 12 weeks will continue until the study close (see
Figure 1 and Additional file 1).
This trial was approved by six sites’ ethics committees
and required archival filing management in five other sites’
ethics committees (Additional file 2).Participants
Patients with a clinical diagnosis of psoriasis plaque (as
diagnosed by a dermatologist during the run-in period)
can be enrolled into this study. A diagnosis of PV is com-
pliant with the guidelines of care for the management of
psoriasis and psoriatic arthritis from the American Acad-
emy of Dermatology and the guideline for the treatment
of psoriasis from the Psoriasis Study Group of Chinese
Medical Association [14,15].
Patient with psoriasis vulgaris
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Figure 1 CMCBCOP trial flow diagram.
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to potential subjects using Mandarin or the local lan-
guage. All potential subjects will be given a consent form
and separate information sheets including information
on the main aspects of the trial. Patients will then be
able to have an informed discussion with their family
and participating consultant. Research assistants will ob-
tain the signed consent form from patients willing to
participate in the trial.Recruitment procedure
Most participants will be recruited through posters in
local newspapers and hospitals; a few patients may spon-
taneously contact trial centers.Inclusion criteria
Patients will be enrolled if they have a clinical diagnosis
of PV, a psoriasis area severe index (PASI) of more than
10 or body surface area (BSA) of more than 10%, but
PASI of less than 30 and BSA of less than 30%, are agedbetween 18 and 65-years-old, and provide signed in-
formed consent.
Exclusion criteria
1. Those with guttate psoriasis, inverse psoriasis or
psoriasis exclusively involving the face
2. Those who are pregnant, lactating, or who plan to
become pregnant within a year
3. A Self-rating Anxiety Scale (SAS) score of > 50 or a
Self-rating Depression Scale (SDS) scale of > 53, or
those with other psychiatric disorders
4. Those with any uncontrolled cardiovascular,
respiratory, digestive, urinary, or hematological disease
5. Those with a known cancer, infection, electrolyte
imbalance, acid-base disturbance or calcium
metabolic disorder
6. An abnormal serum calcium level (Ca2+ > 2.9
mmol/L or < 2 mmol/L)
7. Anyone allergic to any medicine or ingredients used
in this study
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or who have participated in another trial within
a month
9. Anyone who has received topical treatments (such
as corticosteroids or retinoic acid) within 2 weeks,
systemic therapy or phototherapy (ultraviolet
radiation B,UVB and psoralen combined with
ultraviolet A, PUVA) within 4 weeks, or biological
therapy within 12 weeks
10. Acute progression of psoriasis and erythroderma
tendency
11. Patients need systemic treatment prescribed by
doctors
Interventions
Participants in experimental group will receive the
YXBCM01 granule 5.5 g twice daily for 12 weeks. Pla-
cebo granule are given to patients in the placebo group
5.5 g twice daily for 12 weeks, the main ingredients of
which are maltodextrin, lactose, and a natural edible
pigment, will be identical to the YXBCM01 granule in
appearance, weight, and taste. The sequential topical
therapy is administrated simultaneously in all eligible
patients by using a calcipotriol betamethasone ointment
once daily (treatment area up to 30% BSA, one fingertip
unit is recommended) in the first 4 weeks (maximum of
100 g weekly), followed by calcipotriol ointment once daily
in the remaining 8 weeks (maximum of 100 g weekly),
which is recommended on the S3-Guidelines for the treat-
ment of psoriasis vulgaris [5]. The YXBCM01 granule and
the matching placebo used in the trial are manufactured by
the Tianjiang Pharmaceutical Co., Ltd. (Jiangyin, Jiangsu
Province, China) that meets the requirements of the
Good Manufacturing Practice (GMP). The calcipotriol
betamethasone ointment (approval number H20080487)
and calcipotriol ointment (approval number H20050125)
are manufactured by LEO Laboratories Ltd (Ballerup,
Denmark).
Rescue and concomitant treatment
Urea ointment is used as the basic concomitant treat-
ment in the run-in and follow-up period, according to
doctors’ opinion. In cases of patients with serious itch,
cetirizine hydrochloride (1 pill per day) is to be a rescue
drug following the doctor’s advice.
Randomization and blinding
A total of 600 participants will be enrolled from eligible
patients in 11 research sites. A computer-generated ran-
dom list for center-stratified method and permuted blocks
size created by SAS 9.2 software (SAS Institute Inc., Cary,
USA) and performed by the Key Unit of Methodology in
Clinical Research (KUMCR) of Guangdong Provincial Hos-
pital of Chinese Medicine will be used for randomization.The participants will be randomly allocated to two
different treating groups in a 1:1 ratio through the Inter-
active Web Response System for Chinese Medicine
Trials (IWRS-CMT), which was a verified online ran-
domization facility established by the KUMCR.
The randomization schedule will be concealed until
interventions are all assigned and enrollment, follow-up,
data collection, data cleaning, and analysis are complete.
The participants, paramedics, investigators, outcomes
assessors, statistician, and other staff do not know the
treatment allocation, which will not be revealed until the
end of study.
The randomization list and blinding codes will be kept
strictly confidential. Only the KUMCR staff will have
access to the randomization list. Blinding was ensured
using a matched placebo granule identical in color, size,
shape, and taste. The quality of the matched trial sup-
plies, such as contents, solubility, and bacteria contami-
nations, should be controlled rigorously according to
the GMP standards, and be tested and verified by
researchers.
Outcome measures
The primary outcome measure in the trial is relapse inci-
dence rate in the treatment period and follow-up period.
The definition of relapse is a loss of 50% of PASI improve-
ment from baseline in patients who have achieved treat-
ment success (at least 50% improvement in PASI score
from baseline) [16,17]. PASI will be assessed every week
during the first 4 weeks and every 2 weeks throughout
the rest of the treatment and follow-up period. Mean-
while, patients will be required to report the emergency
of skin lesions at any time in the study period, and
researchers will assess the PASI score on the same or
closest day.
Secondary outcome measures include time to relapse,
time to onset, rebound rate, PASI score, cumulative con-
sumption of topical medicine, visual analogue scale (VAS),
BSA, DLQI, and SF-36 (the MOS item short form health
survey).
Time to relapse is defined as the time to loss of at
least 50% of the PASI improvement for the first time.
Time to onset is time taken for the PASI score to de-
crease more than 50% for the first time, and treatment
will be considered as ineffective when the PASI score
cannot get 50% improvement throughout the treatment
period. Rebound refers to a PASI score increasing of
more than 125% above baseline, or occurring of new
generalized pustular and erythrodermic after its im-
provement (PASI-50) during the study period. The VAS
and BSA will be assessed every week during the first
4 weeks and every 2 weeks throughout the rest of the
treatment period. The DLQI and SF-36 will be self-
assessed by patients every 4 weeks throughout this trial.
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Participants are to be questioned and report all adverse
events (AEs) at each visit point, and all AEs reports will
be recorded and assessed by the investigators. A blood
test, urinalysis, hemagglutination test, and electrocardio-
graph examination will be checked before and after the
treatment. Furthermore, calcium, kidney, and liver func-
tion tests will be reexamined at week 4 and week 12,
respectively. All abnormal changes from the baseline of
lab test will be evaluated.
Sample size calculation
Based on White et al.’s study [18], the relapse rate of
sequential topical therapy 12 weeks is 37.3%, and pla-
cebo is 46.6%. For example, suppose the relapse rate of
YXBCM01 granule combined with sequential topical ther-
apy for PV in the twelfth week is 20%, sequential topical
therapy alone is 37%. According to the supposition and as
calculated by PASS 11.0 software (NCSS, LLC, Kaysville,
Utah, USA), sample size of 239 in each group can achieve
90% power and to rule out a two-sided type I error of 5%
to detect a superiority margin difference of 10% in this
two-arm trial with equal allocation in each group. Consid-
ering 15 to 20% loss to follow-up, the total sample size
should be adjusted to 300 in each group.
Data management and quality control
The data collected in this trial comprises of information
recorded in case report forms and information on the
DLQI and SF-36 scale. When every visit was completed
at each center, data will be entered using the double
entry method.
To ensure that outcome assessments are of a high
standard in accordance with the trial protocol, physi-
cians, assessors, and research assistants will attend six-
hours training workshop before the conduction of trial.
They will also be provided with a written protocol and
standard operation procedures documents. All the data
in different sites will be checked regularly by researchers
from GPHCM and be overseen by monitors. The moni-
toring tasks of the trial will be entrusted to Guangdong
International Clinical Research Center of Chinese Medi-
cine (Guangzhou, China). The auditing and inspection
of the trial will be performed by the Department of
Science Research of GPHCM and the Office of National
Key Technology R&D Program for the Twelfth Five-year
Plan of Ministry of Science and Technology, China. The
Data Monitoring Committee from GPHCM will assess
the safety data and the critical efficacy outcomes.
Participants may withdraw from the study at any time
for any reason. If any patients wish to withdraw, clini-
cians should ask if they would be willing to complete the
assessments as according to the study schedule and write
down their last time of taking the medicine. Incidences ofpatient loss to follow-up and withdrawal will be recorded
and reported.
Statistical analysis
Data analysis will follow with the statistical analysis plan
for this trial. Data will be processed by statistical analyses
with PASW Statistics 18.0 (IBM SPSS Inc., Armonk, New
York, USA) and SAS 9.2 software (SAS Institute Inc.,
Cary, USA). Two-tailed P values <0.05 are considered to
be statistically significant. Analysis will be on intention-to-
treat and per-protocol subject principles. The baseline
characteristics of patients in two groups will be reported.
The primary outcome, relapse rate, will be compared be-
tween both groups at 12 weeks and 24 weeks after treat-
ment using Chi-square test, and considering superiority
comparison between two groups by 95% confidence inter-
val method. The secondary outcomes will be summarized
with frequency, mean, standard deviation, median, and
range. At one time point, comparisons between the ex-
periment group and the placebo group will be conducted
using the t-test. In order to distinguish the treatment ef-
fect and time effect, changes from baseline in the above
outcomes will be tested using repeated measure analysis
of variance. The analysis of covariance or logistic regres-
sion model will be used to analyze the site effect and im-
pact factors. The co-variables will include gender, age,
concomitant drugs, disease course, BSA, and PASI at the
baseline visit. The subgroup analysis will be performed
based on the severity of disease and CM patterns. Adjust-
ing for baseline covariates, for timed endpoints such as
time to relapse and time to onset, we will use the Kaplan-
Meier survival analysis followed by the multivariable Cox
proportional hazards model for adjusting for baseline
variables. To assess the impact of potential clustering for
patients cared for by the same hospital, we will use gener-
alized estimating equations (GEE) assuming an exchange-
able correlation structure.
Safety will be evaluated by tabulations of adverse events
and will be presented with descriptive statistics at baseline
and follow-up visits for each group. The statistics will be
organized by treatment phase and post-treatment phase as
appropriate. Chi-square test or Fisher’s exact test will be
used to compare the frequency difference of adverse
events between the experimental and control group. As
cases are divided into different degrees of AE, the rank-
sum test will be performed for analyzing the independ-
ent ordered multiple category data between two groups.
Discussion
Chinese herbs have been widely used in China and other
Asian countries over years. Simultaneously, dozens of
Chinese herbal studies in vivo or vitro were conducted
to figure out the ingredients or pharmacological mecha-
nisms. In a rice model, oral administration of Sarcandra
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acid, isofraxidin and so on) could alleviate the stress-
induced reduction of the number of lymphocytes, the
balance of CD4 + T/CD8 + T and natural killer cell activ-
ity per spleen [19]. Niu et al. [20] examined that arthritic
mice treated with isofraxidin (IF) had an obvious differ-
ence in serum tumor necrosis factor-α (TNF-α) compared
with the lipopolysaccharides-stimulated group, IF may
possess significant anti-inflammatory activities. Astilbin
isolated from Rhizoma Smilacis Glabrae, inhibited the
footpad swelling, arthritic incidence, and clinical scores
without losing body weight [21]. The previous pharmaco-
logical properties of Sarcandra Glabra extract or Rhizoma
Smilacis Glabrae may at least partially explain the clinical
benefits for the YXBCM01 formula.
The inhibitory effect of the YXBCM01 formula has
also been shown on the epithelial cell mitosis of mice
[22]. Furthermore, the effect on proliferating cell nuclear
antigen (PCNA) presentation and keratinocytes (KC)
apoptosis was studied through different dose lavage in
mice, in which high dose had a remarkable influence on
PCNA inhibition and COLO-16 apoptosis [23]. Also, the
YXBCM01 decoction was found to significantly inhibit
the mitosis of mouse vaginal epithelium and promote
the formation of granular layers in mouse tail-scale
epidermis, and inhibit human keratinocyte line HaCat
cells growth remarkably, when compared with the saline
control group [24]. Among the five main constituents in
the YXBCM01 formula, isofraxidin was found to be the
active constituent for its correlation with the pathogen-
esis of psoriasis, with astilbin as the helper constituent
due to its relationship with the transportation of drug
molecules [25].
Some studies have shown that CM agents are effective
and safe in the treatment of psoriasis. A randomized trial
was conducted to compare CM combined with an aci-
tretin capsule with CM alone [8]; the adverse reaction of
the acitretin capsule could be alleviated by adjusting the
herbs used. In another randomized control trial, 78 pa-
tients were randomly assigned to two groups: oral CM
decoction (30 patients), or compound amino-polypeptide
tablet (28 patients) [26]. At 4 weeks, there was an increase
significantly between CM group (83.33%) and control
group (64.28%) in the total response rate of PASI. Quality
of life improvement in the CM group was superior to that
the control. Similarly, Gao and Xu [27] demonstrated that
a compound amino-polypeptide tablet combined with a
CM decoction (94.29%) had an advantage over amino-
polypeptide (83.33%) or CM decoction alone (62.86%) in
PASI reduction. The incidence of adverse events in the
CM group was less than that in amino-polypeptide and in-
tegrated group, as well as the relapse rate. However, the
research quality was low and the definition of relapse was
not declared. Remission seems to be long lasting and lesscostly compared with other treatments or biologic agents
[28], but the relapse rate of CM treatment has not been
proved in randomized controlled trials before.
A pilot study is necessary and important to demonstrate
the feasibility of this trial, which has been performed to
inform the design, from August 2012 to July 2013 in
Guangzhou, China. It used the same add-on designed,
double-blinded, randomized controlled trial comparing
the YXBCM01 granule to placebo. The results showed the
relapse rate in the YXBCM01 granule group was 28.6% (2
out of 7 patients) versus 70% (7 out of 10 patients) in the
placebo group. While the result was not against our sup-
position of sample size calculation, we revised some de-
tails in the study design after this pilot study and it paved
the way for patient recruitment and trial conducting.
As a randomized controlled trial of CM for psoriasis,
it is unusual that both the CM granule and placebo groups
receive topical therapy treatment. We aim to conduct this
trial to demonstrate both the efficacy and safety of the
YXBCM01 formula for PV patients, and consider that a
conscientiously performed trial and effective outcomes
will benefit PV patients. If this trial provides high-quality
evidence for the efficacy and safety of the YXBCM01
formula, it will provide useful clinically information for
PV, especially for reducing the relapse of disease in PV
patients.
Trial status
The pilot phase of the trial started in August 2012 in the
Guangdong Provincial Hospital of Chinese Medicine,
China and is still in progress.
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